Pharma BD Deal Intelligence
A multi-year collaboration pairing Illumina's population-scale sequencing with Amgen's deCODE genetics database of 500,000+ consented participants to mine drug targets. A pure discovery-stage bet with no disclosed financial terms, its payoff hinges entirely on whether the genomic target ID work converts into an actual pipeline.
Illumina and Amgen entered a multi-year collaboration to leverage Illumina's population-scale genomics capabilities and Amgen's proprietary deCODE genetics database to advance drug discovery and development. The collaboration utilizes whole genome sequencing data from deCODE's database of more than 500,000 consented participants. Financial terms were not publicly disclosed.
Multi-year collaboration leveraging Illumina genomics and Amgen deCODE genetics database for drug discovery.
Illumina/NashBio Alliance for Genomic Discovery — of which Amgen is one of eight biopharma members and deCODE (Amgen) is the sequencing provider — completed 250,000 whole genomes. Adjacent to the 2020 bilateral collaboration; reinforces the active Amgen-Illumina genomics relationship.
Ongoing discovery collaboration. Whole genome sequencing applied to drug target identification.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Illumina, Inc. / Amgen Inc. (this deal) | 2020 | — | 56 |
| Illumina, Inc. / GRAIL, Inc. | 2020 | $8.0B | 36 |
| Illumina, Inc. / GRAIL, Inc. | 2021 | $7.1B | — |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. | 2020 | $2.0B | 91 |
| Novo Nordisk A/S / Emisphere Technologies | 2020 | $1.4B | 90 |
← Browse all deals · How we score deals
More: 2020 deals · Illumina, Inc. deals